Newron Pharmaceuticals SpA (FRA:NP5) Moat Score: 3/10 (As of Jul. 02, 2026)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
64 GF Score
Price €13.40
GF Value €13.49
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Moat Score?

Newron Pharmaceuticals SpA FRA:NP5 -3.94% 64 Moat Score is 3 as of Jul. 02, 2026. GuruFocus rates FRA:NP5 with a GF Score™ of 64/100 and a GF Value™ of €13.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,400 Biotechnology companies, Newron Pharmaceuticals SpA ranks better than 75.5% on this metric.

Newron Pharmaceuticals SpA has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Newron Pharmaceuticals SpA has No Moat: Newron Pharmaceuticals SpA has some intellectual property in pharmaceuticals, but lacks the scale, brand strength, and regulatory advantages to establish a strong competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Newron Pharmaceuticals SpA might have No Moat - Very weak/transient advantages.

Newron Pharmaceuticals SpA  (FRA:NP5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Newron Pharmaceuticals SpA Moat Score Related Terms

FRA:NP5 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Newron Pharmaceuticals SpA Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Moat Score distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Moat Score falls into.


FRA:NP5
64GF Score
Newron Pharmaceuticals SpA FRA:NP5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a Moat Score of 3 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Newron Pharmaceuticals SpA's Moat Score too high?
Newron Pharmaceuticals SpA's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Newron Pharmaceuticals SpA's value of 3 is 50% above this industry median. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #343 out of 1400 companies for Moat Score. This places Newron Pharmaceuticals SpA in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Newron Pharmaceuticals SpA's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newron Pharmaceuticals SpA's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.49, compared to a current price of €13.40 — trading 0.7% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Moat Score is 3 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.40 is trading 0.7% below its estimated GF Value™ of €13.49. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • Moat Score: 3
  • GF Value™: €13.49 vs. price of €13.40 (0.7% below fair value)
  • GF Score™: 64/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1400)

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for FRA:NP5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.40
Price
€13.49
GF Value